An $8,000 investment in these biotech stocks 10 years ago would be worth over $250,000 today. Are more gains ahead?
News & Analysis: Medivation, Inc.
Pfizer's forking out $14 billion in cash, but the deal significantly builds out the drugmaker's oncology lineup.
An EpiPen pricing debacle, an unexpected FDA rejection, and a sticker-shock inspiring M&A deal led to wild moves in Mylan N.V., Portola Pharmaceuticals, and Medivation shares this week.
Medivation, Acadia Pharmaceuticals, and LendingTree have delivered jaw-dropping returns over the past five years.
ExxonMobil, Microsoft, and Pfizer are top stocks that offer retirees an attractive blend of risk, reward, and dividend upside.
Pfizer is paying $81.50 per share in cash to acquire Medivation's oncology drugs.
Why Medivation and Marathon Oil shares made big moves as the indexes barely budged on Monday.
Confirmation of a buyout offer from pharma giant sends shares of Medivation higher.
Seemingly half the world's pharma companies are chasing this relatively unknown biotech. Here's why.
Twenty baggers are a rare breed, but these three companies have earned that title in just the last decade.